BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Axcellerate Pharma aims to become a market leader

27 November 2013 | News | By BioSpectrum Bureau

Axcellerate Pharma aims to become a market leader



Axcellerate Pharma establishes CMO/CRO and API manufacturing facility in New Jersey, US. Focus will be small molecule and biologics PR& D, innovative technology platforms, filling vial and bag operations, peptide synthesis, oligonucleotide production and related areas.

Axcellerate Pharma LLC ("Axcellerate") is a JV set up by TCG Lifesciences Ltd, a leading CRO engaged in drug development and clinical trial services; with Mr Dilip Mehta, founder & CEO of PANORAMA consulting and Engineering, Inc., a prime developer of lab scale to GMR manufacturing facilities. The facility houses state-of-the-art technology/ equipment/ infrastructure and is supported by leading industry personnel from each of the partner firms.

"We will initially target specialized CMC and CMO activities that are time sensitive and high value in nature, that are desirable to be located geographically close to our clients. Axcellerate intends to leverage the strong scientific talent pool, end-to-end capabilities and PR&D/ intermediate production facilities of TCG Lifesciences Limited in India to support its operations. this opportunity represents another significant milestone for TCG Lifesciences' continued expansion," commented Mr Swapan Bhattacharya, managing director of TCG Lifesciences. "As this strategic alliance will expand TCG Lifesciences' geographic footprint and enable us to service clients in the US with a local presence while being supported globally" further he added.

Mr Dilip Mehta, CEO and co-founder of Axcellerate commented "we will engineer the facilities to provide the highest level of efficiency, technology and cost effectiveness to our customers, given PANORAMA's broad involvement and experience in all facets of the pharma/biotech sector. We are pleased to join hands with TCG Lifesciences, who will bring in the scientific and technical know how and expertise in the cutting edge areas of drug discovery and development."

"AlfaGene Bioscience has developed proprietary assay platforms in a range of therapeutic indications and has a scientific team with extensive experience in biologics and biomedical research. We also have a network of global relationships in the API arena to bring to bear for the success of Axcellerate"' remarked Mr Mayur Doshi, president and CEO, AlfaGene Bioscience.